Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), scheduled for May 12-16, 2026 in Padua, Italy. The event, hosted by the University of Padova, is the world’s largest gathering of congenital cardiology specialists, drawing over 1,000 clinicians from 32 European countries and beyond. This year’s scientific program centers on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is making significant clinical advances.
Ventripoint will share a booth with its European distributor, AngioPro, to engage with clinicians from the global congenital cardiology community. A key focus will be the use of VMS+™ to track cardiac function over time in congenital heart disease (CHD) patients. The importance of this approach is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the primary modality for longitudinal assessment of ventricular function (Baumgartner et al., European Heart Journal, 2021; doi:10.1093/eurheartj/ehaa554).
Ventripoint’s priority for 2026 is accelerating the integration of VMS+™ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients. The latest release, VMS+™ 4.0, was designed around clinician needs, streamlining workflows and reducing the time required to generate assessments. At the point of a patient’s first echocardiogram, VMS+™ provides accurate volumetric cardiac measurements equivalent to MRI, delivering detailed insights early in the care journey to support clinical decision-making and effective patient management over a lifetime.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint’s flagship VMS+™ product family is powered by proprietary KBR technology, the result of more than a decade of development, and delivers volumetric cardiac measurements with accuracy equivalent to MRI. VMS+™ is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada.
